MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a …

… first quarter of fiscal 2026 ended November 30, 2025 (Q1 … "During the first quarter of fiscal 2026, … financial foundation". First Quarter 2026 Financial Highlights Cash … and development expenditures incurred through Cynaptec Pharmaceuticals, Inc., …

… and weather disruptions. First-quarter results showed declining … completed previously, reduced first-quarter sales by approximately $ … microbial protection, and pharmaceutical excipients. The company … million initiative. Capital expenditures for the full year …

… results1 for the first quarter of fiscal year … pharmaceuticals, personal care and architectural coatings. “Ashland’s first‑quarter … discipline,” Novo concluded. First-quarter sales were $386 … mandatory versus discretionary expenditures can vary significantly …

… continues to develop. In the first quarter, we made targeted, deliberate … are currently working with large pharma companies who are building … was $24.8 million. Capital expenditures in 2026 were $10 million … our Q4 and Q1. And it’s the first quarter we felt we …

… production in existing facilities across pharmaceuticals, chemicals, steel, and other … million at quarter end. Capital expenditures were $4.9 million for … off somewhat in Q4 and Q1 and then begin to rebuild … we've in the first quarter of this year, we had …

SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1 52 Week data, pending positive results and planned …

… the tone, as capital expenditures continue apace. Plus, the … outlook. In the fiscal first quarter, the company said revenue … ride-hailing giant issued first quarter profit guidance that disappointed … on Wednesday after the pharmaceutical group provided a 2026 …

… From a segment standpoint, first-quarter dispensing and specialty closures adjusted … have an impact on Q1 volumes for the dispensing … functioning, your position in pharmaceuticals and health care and … know, our two largest expenditures that we have and …

… January 30, 2026 Regeneron Pharmaceuticals, Inc. beats earnings expectations … regulatory application in the first quarter with potential approval … demand growth in the first quarter while EYLEA demand … also expect 2026 capital expenditures to be in the …